Loss of DBC2 Expression is an Early and Progressive Event in the Development of Lung Adenocarcinoma

  • Dong, Wei (Institute of Oncology, Provincial Hospital affiliated to Shandong University, Shandong University) ;
  • Meng, Long (Department of Thoracic Surgery, Provincial Hospital affiliated to Shandong University, Shandong University) ;
  • Shen, Hong-Chang (Institute of Oncology, Provincial Hospital affiliated to Shandong University, Shandong University) ;
  • Du, Jia-Jun (Institute of Oncology, Provincial Hospital affiliated to Shandong University, Shandong University)
  • Published : 2012.05.30


Purpose: DBC2 (Deleted in Breast Cancer 2) has been indicated to be a tumor suppressor gene in many cancers including lung adenocarcinoma recently. In this study, we aimed to explore the expression status of DBC2 in different subtypes of lung adenocarcinoma (from pre-invasive to invasive lesions), and to determine if downregulation becomes more marked with pathological progression. Methods: We collected 172 tissue samples from different subtypes of lung adenocarcinoma and investigated the frequency of DBC2 loss by immunohistochemistry. Results: Our results indicated that DBC2 downregulation is a relatively frequent event in lung adenocarcinoma. Moreover, as the adenocarcinoma subtype turns to be more invasive, more downregulation occurred. Conclusion: We conclude that loss of DBC2 expression is an early and progressive event in the pathogenesis of lung adenocarcinoma. Positive DBC2 immunohistochemistry may become an indicator for early stage disease and better prognosis of lung adenocarcinomas.


  1. Akita H (2004). [Molecular biology of lung cancer]. Nihon Kokyuki Gakkai Zasshi, 42, 378-86.
  2. Bova GS, Carter BS, Bussemakers MJ, et al (1993). Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res, 53, 3869-73.
  3. Chang FK, Sato N, Kobayashi-Simorowski N, et al (2006). DBC2 is essential for transporting vesicular stomatitis virus glycoprotein. J Mol Biol, 364, 302-8.
  4. Collado D, Yoshihara T, Hamaguchi M (2007) DBC2 resistance is achieved by enhancing 26S proteasome-mediated protein degradation. Biochem Biophys Res Commun, 360, 600-3.
  5. Emi M, Fujiwara Y, Nakajima T, et al (1992). Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res, 52, 5368-72.
  6. Fujiwara Y, Emi M, Ohata H, et al (1993). Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res, 53, 1172-4.
  7. Hamaguchi M, Meth JL, von Klitzing C, et al (2002). DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA, 99, 13647-52.
  8. Hou XZ, Liu W, Fan HT, et al (2010). Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas. Neuro Oncol, 12, 799-803.
  9. Knowles MA, Aveyard JS, Taylor CF, Harnden P, Bass S (2005) Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett, 225, 121-30.
  10. Koga T, Hashimoto S, Sugio K, et al (2001). Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. Clin Cancer Res, 7, 1730-8.
  11. Lundgren R, Mandahl N, Heim S, et al (1992). Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes Cancer, 4, 16-24.
  12. Mao H, Qu X, Yang Y, et al (2010). A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer. Mol Carcinog, 49, 283-9.
  13. Mao H, Zhang L, Yang Y, et al (2011). RhoBTB2 (DBC2) functions as tumor suppressor via inhibiting proliferation, preventing colony formation and inducing apoptosis in breast cancer cells. Gene, 486, 74-80.
  14. Merel K, Rosana N, Stephen J, et al (2012). The burden of cancer in member countries of the association of southeast asian nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20.
  15. Nakano H, Soda H, Takasu M, et al (2008). Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer, 60, 136-40.
  16. Pao W, Girard N (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncol, 12, 175-80.
  17. Raz DJ, He B, Rosell R, Jablons DM (2006). Current concepts in bronchioloalveolar carcinoma biology. Clin Cancer Res, 12, 3698-704.
  18. Siripurapu V, Meth J, Kobayashi N, Hamaguchi M (2005). DBC2 significantly influences cell-cycle, apoptosis, cytoskeleton and membrane-trafficking pathways. J Mol Biol, 346, 83-9.
  19. Sunwoo JB, Holt MS, Radford DM, Deeker C, Scholnick SB (1996). Evidence for multiple tumor suppressor genes on chromosome arm 8p in supraglottic laryngeal cancer. Genes Chromosomes Cancer, 16, 164-9.<164::AID-GCC2>3.0.CO;2-X
  20. Travis WD, Brambilla E, Noguchi M, et al (2011). International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 6, 244-85.
  21. Wang G, Dong W, Shen H, et al (2011). A comparison of Twist and E-cadherin protein expression in primary non-smallcell lung carcinoma and corresponding metastases. Eur J Cardiothorac Surg, 39, 1028-32.
  22. Wistuba, II, Behrens C, Virmani AK, Milchgrub S, et al (1999). Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res, 59, 1973-9.
  23. Xiao H, Ding J, Gao S, Yang S, Huang Y (2011). Never smokers with lung cancer: analysis of genetic varients. Asian Pac J Cancer Prev, 12, 2807-9.
  24. Yoshihara T, Collado D, Hamaguchi M (2007). Cyclin D1 downregulation is essential for DBC2's tumor suppressor function. Biochem Biophys Res Commun, 358, 1076-9.

Cited by

  1. Hsp90-Dependent Assembly of the DBC2/RhoBTB2-Cullin3 E3-Ligase Complex vol.9, pp.3, 2014,
  2. Atypical Rho GTPases of the RhoBTB Subfamily: Roles in Vesicle Trafficking and Tumorigenesis vol.5, pp.2, 2016,
  3. DBC2/RhoBTB2 functions as a tumor suppressor protein via Musashi-2 ubiquitination in breast cancer vol.36, pp.20, 2017,